Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Assessing the Association of Circulating Tumor Cells with Aberrant ALK Copy Number to Predict Clinical Outcomes of Treatment with ALK-Inhibitors (Crizotinib and Lorlatinib) in ALK-Rearranged Non-Small Cell Lung Cancer Patients

Next Previous
X
Search
Trial Profile

A Study Assessing the Association of Circulating Tumor Cells with Aberrant ALK Copy Number to Predict Clinical Outcomes of Treatment with ALK-Inhibitors (Crizotinib and Lorlatinib) in ALK-Rearranged Non-Small Cell Lung Cancer Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary) ; Lorlatinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 22 Aug 2019 Results assessing resistance to an ALK-inhibitor using CTCs isolated at the single-cell level from patients at disease progression on crizotinib (n=14) or lorlatinib (n=3), were published in the Clinical Cancer Research Journal.
    • 01 May 2017 Results (n=39) assessing association between ALK-rearranged and ALK-CNG CTC subsets and clinical parameters, including PFS and overall survival (OS), were published in the Cancer Research Journal.
    • 28 Jul 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top